4 papers in the library · 38 citations · publishing 2023-2026
Br J Pharmacol June 16, 2026 György Bagdy, Dóra Pothorszki, Noémi Papp et al.
Variability in the effects of ketamine enantiomers across animal models of depression and implications for human studies.
British Journal of Pharmacology June 1, 2026 Szabolcs Koncz, Dóra Pothorszki, Noémi Papp et al. 2 citations
Ketamine consists of two enantiomers, (R)-ketamine and (S)-ketamine, which exhibit distinct pharmacological properties. Currently, only the (S)-enantiomer has been approved for the treatment of major depressive disorder, whereas recent clinical studies have failed to demonstrate an antidepressant effect for (R)-ketamine. The quantitative electroencephalography (qEEG) gamma-enhancing effect of...
Pharmaceuticals (Basel, Switzerland) February 1, 2024 Dóra Pothorszki, Szabolcs Koncz, Dóra Török et al. 7 citations
Differences in the pharmacological effects of (S)-ketamine and (R)-ketamine are at the focus of research. Clinical data and our rat studies confirmed the antidepressant effect of (S)- but not (R)-ketamine, with similar differences in quantitative electroencephalogram (EEG) and sleep effects. In contrast, studies mainly on mice showed some stronger, preferable effects of (R)-ketamine. EEG theta...
International Journal of Neuropsychopharmacology September 25, 2023 Szabolcs Koncz, Noémi Papp, Dóra Pothorszki et al. 29 citations
Abstract Background Racemic ketamine consists of two enantiomers, namely (R)-ketamine and (S)-ketamine, with distinguishable pharmacological properties. Both enantiomers have been reported to show rapid antidepressant effects in rodents. Currently, the (S)-enantiomer has been approved for the treatment of major depression, whereas (R)-ketamine failed to show antidepressant effect in recent...